This phase II trial studies how well gruticibart works in reducing the incidence of catheter-related thrombosis (CRT) blood clots in patients with a central venous catheter (CVC) inserted. Many patients develop blood clots from their catheters and can have pain, swelling, and other symptoms. They also often require blood thinners, which can increase the risk of bleeding. Gruticibart, a type of drug called a monoclonal antibody, may prevent blood clots caused by a catheter.

PRIMARY OBJECTIVE(S):

I. To determine the safety of gruticibart as measured by the incidence of CRT in individuals with a CVC II. To determine the efficacy of gruticibart as measured by the incidence of CRT in individuals with a CVC II. To determine the efficacy of gruticibart as measured by the incidence of CRT in individuals with a CVC

SECONDARY OBJECTIVES:

I. To evaluate the safety and tolerability of gruticibart in patients with a CVC II. To determine the efficacy of gruticibart as measured by the time to CRT and incidence of any thrombosis in individuals with a CVC

OUTLINE: Participants are randomized to 1 of 2 arms.

Arm A. Participants receive single dose of placebo IV via CVC or peripheral IV line.

Arm B. Participantsreceive single dose of gruticibart (2 mg/kg) IV via CVC or peripheral IV line.

After completion of study treatment, participants will be followed for AEs for a total of 30 days from time of administration of study drug, and are considered off-study after 30 days. .

Inclusion Criteria:

• Ability to understand and the willingness to sign a written informed consent document.

• Men and women, aged ≥ 18 years.

• In consultation with PI and treating physician, participant's therapy allows for a 1 to 2-day period between administration of study drug and subsequent start of planned therapy.

• Individuals that will undergo insertion of a CVC as part of planned therapy per institutional standards.

• Must have ECOG performance status ≤ 2 (refer to Appendix A).

• At time of enrollment, must have:

  • Platelet count > 50 x 109/L

• Female participants of childbearing potential must have a negative urine or serum pregnancy test during screening and at check-in Day -1. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.

• Participants of childbearing potential are defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) and is not postmenopausal.

• Female participants of childbearing potential must agree to use two forms of highly effective contraception (Appendix B) starting with the first dose of study therapy through 90 days after the last dose of study therapy.

Participants of childbearing potential are those who have not been surgically sterilized or have not been free from menses for >1 year without an alternative medical cause.

• Male participants must agree to use an adequate method of contraception starting with the first dose of study therapy through 90 days after the last dose of study therapy.

Exclusion Criteria:

• Concurrent enrollment in another therapeutic clinical trial

• Active leukemia (lymphoma and myeloma may be included)

• Primary brain tumors or known brain metastases

• Active infection and/or current use of an oral antibiotic

• At time of enrollment:

  • Deranged baseline clotting, where INR > 1.5
  • Known bleeding diathesis
  • Use of anticoagulation, either therapeutic or prophylactic, for any indication at enrollment

• -At the discretion of the investigator, any other contraindication to anticoagulation therapy

• Previously documented hypersensitivity to either the drug or excipients.

• Psychiatric illness/social situations, or any other condition, that in the opinion of the investigator, would limit compliance with study requirements.

• Participant is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 90 days after study drug administration.